DDInter583 DDInter1376
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Donepezil {u} (Compound) resembles {v} (Compound) Doxazosin
Donepezil {u} (Compound) resembles {v} (Compound) Moexipril
Donepezil {u} (Compound) treats {v} (Disease) Alzheimer's disease
Donepezil {u} (Compound) binds {v} (Gene) CYP2D6
Donepezil {u} (Compound) upregulates {v} (Gene) MAPKAPK5
Donepezil {u} (Compound) downregulates {v} (Gene) CCNB2
Donepezil {u} (Compound) causes {v} (Side Effect) Abdominal pain upper
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zafirlukast
Donepezil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Donepezil (Compound) resembles Doxazosin (Compound)
Donepezil (Compound) resembles Moexipril (Compound)
Donepezil (Compound) treats Alzheimer's disease (Disease)
Donepezil (Compound) binds CYP2D6 (Gene)
Donepezil (Compound) upregulates MAPKAPK5 (Gene)
Donepezil (Compound) downregulates CCNB2 (Gene)
Donepezil (Compound) causes Abdominal pain upper (Side Effect)
Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Donepezil may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin